Germany Archives

News and Trends 6 Jan 2020

BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice

A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential for tackling solid tumors, which are hard to treat with current CAR T-cell therapies. In a study published in Science, the CAR T-cell and RNA combination therapy suppressed tumors in mice implanted with human ovarian cancer for longer than regular […]

January 6, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2019

German Startup Raises €4M Seed Round to Make Dairy Cheese Without Milk

Berlin-based startup Legendairy Foods has raised €4M to develop cheese and other dairy products that have the same composition as milk but are not derived from animals. The fundraising was co-led by food tech investor Agronomics and M Ventures, the corporate venture capital arm of Merck. CPT Capital, an investor in alternative proteins, […]

December 20, 2019 - 1 minutemin - By Clara Rodríguez Fernández

colorectal cancer mologen cancer immunotherapy

News and Trends 6 Dec 2019

Update: Cancer Immunotherapy Biotech Files for Insolvency

Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […]

December 6, 2019 - 2 minutesmins - By Jonathan Smith

acute heart failure 4teen4 pharmaceuticals

More News! 5 Dec 2019

German Biotech Raises €7M Series A to Treat Acute Heart Failure

4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was led by Brandenburg Kapital, a subsidiary of the German investment bank Investitionsbank des Landes Brandenburg. Other investors in the round, including business angels and private […]

December 5, 2019 - 2 minutesmins - By Jonathan Smith

vigeneron germany gene therapy adenoviral vector

More News! 28 Nov 2019

German Biotech to Develop Next-Generation Gene Therapy for Blindness

The German biotech ViGeneron has raised an undisclosed sum in a Series A round to fund the development of an ophthalmic gene therapy that could deliver bigger DNA sequences into a wider range of cells than current technology. The round was led by two Chinese investors, the VC firm Sequoia Capital China and the pharma […]

November 28, 2019 - 2 minutesmins - By Jonathan Smith

centogene rare diseases diagnostic ipo nasdaq

News and Trends 7 Nov 2019

€51M Nasdaq IPO Will Fund Centogene’s Rare Disease Diagnostics

The German company Centogene has raised €50.6M ($56M) in an IPO on the Nasdaq Stock Exchange to fund the development of diagnostics technology that could improve the treatment of rare diseases. The fundraise fell under Centogene’s target value of €54M ($60M). A part of the proceeds will fuel the development of biomarkers that Centogene will […]

November 7, 2019 - 2 minutesmins - By Jonathan Smith

Best in Biotech 4 Nov 2019

Top 10 Biotech Companies Leaving a Mark in Munich

These are the top 10 biotech companies in Munich, one of the hottest hubs for the biotechnology industry. One of the largest cities in Germany, Munich is a hub for science and technology. Biotechnology is one of its many strengths, supported by strong academic research at the city’s two top universities: Ludwig Maximilian University and […]

November 4, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

alzheimers disease treatment vivoryon therapeutics

News and Trends 24 Oct 2019

German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround

The German company Vivoryon Therapeutics has raised €43M on Euronext Amsterdam to fund a phase IIb trial of a drug that could slow the progression of Alzheimer’s disease by blocking toxic forms of the protein amyloid-beta. Vivoryon Therapeutics, previously known as Probiodrug, raised the money using a rights offering and a private placement on Euronext […]

October 24, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 10 Oct 2019

Update: BioNTech Files for €141M Nasdaq IPO

BioNTech’s Nasdaq IPO has raised €141M ($155M), a lower sum than it initially anticipated. The timing of the IPO means it has likely been impacted by adverse market conditions, which are due to factors such as global manufacturing slowdowns and escalations in US and Chinese trade disputes. This same market volatility led several companies such […]

October 10, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Sep 2019

German Biotech Will Develop Carbohydrate-Targeting Cancer Treatments

The German startup Tacalyx has raised €7M in a seed round to fund the preclinical development of first-in-class carbohydrate-targeting antibody drugs for the treatment of cancer. The round was co-led by the Germany-based Boehringer Ingelheim Venture Fund and the French VC firm Kurma Partners. Tacalyx will use the money to generate a lead candidate antibody […]

September 25, 2019 - 2 minutesmins - By Jonathan Smith

grunenthal mesoblast chronic low back pain

News and Trends 11 Sep 2019

Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy

The German pharmaceutical company Grünenthal has licensed a donor cell therapy for chronic low back pain from the Australian biotech Mesoblast in a deal that could be worth over €900M. Under the terms of the deal, Grünenthal will gain exclusive rights to commercialize Mesoblast’s cell therapy for chronic low back pain in Europe and Latin […]

September 11, 2019 - 2 minutesmins - By Jonathan Smith

celgene immatics cancer cell immunotherapy

News and Trends 28 Aug 2019

Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies

The US company Celgene has obtained options to three cancer immunotherapy programs from the German biotech Immatics in a deal worth more than €1.35B ($1.5B). Immatics is to receive an upfront payment of €67.5M ($75M), along with up to €455M ($505M) in developmental milestones and royalties for each immunotherapy program. In each program, Immatics will […]

August 28, 2019 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Germany

BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice

German Startup Raises €4M Seed Round to Make Dairy Cheese Without Milk

Update: Cancer Immunotherapy Biotech Files for Insolvency

German Biotech Raises €7M Series A to Treat Acute Heart Failure

German Biotech to Develop Next-Generation Gene Therapy for Blindness

€51M Nasdaq IPO Will Fund Centogene’s Rare Disease Diagnostics

Top 10 Biotech Companies Leaving a Mark in Munich

German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround

Update: BioNTech Files for €141M Nasdaq IPO

German Biotech Will Develop Carbohydrate-Targeting Cancer Treatments

Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy

Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!